Ascidian Unveils RNA Editing Data for Genetic Blindness

BOSTON, MA – April 28, 2026 – A new chapter in the fight against inherited blindness is set to be unveiled as Boston-based Ascidian Therapeutics announces it will present the first-ever human safety data for its lead drug candidate, ACDN-01. The data, from the Phase 1/2 STELLAR trial for Stargardt disease, will be a highlight of the upcoming American Society of Gene & Cell Therapy (ASGCT) annual meeting in May.

This presentation marks a critical milestone not only for patients with Stargardt disease, the most common form of inherited macular degeneration, but also for the field of genetic medicine. Ascidian is pioneering a novel technology known as RNA exon editing, a method that seeks to correct genetic diseases by rewriting RNA messages rather than permanently altering a person's DNA. The initial clinical safety results for ACDN-01 will offer the first glimpse into how this groundbreaking approach performs in human patients, providing a crucial validation for the platform's potential.

A New Frontier in Treating Inherited Blindness

Stargardt disease is a devastating condition that typically begins in childhood or adolescence, causing progressive vision loss that often leads to legal blindness. It is caused by mutations in the ABCA4 gene, which is responsible for creating a protein that clears toxic byproducts from retinal cells. Without this protein, these byproducts accumulate and destroy light-sensing cells in the macula.

For years, developing a gene therapy for Stargardt has been hampered by a significant technical hurdle: the sheer size of the ABCA4 gene. It is too large to fit inside the standard adeno-associated virus (AAV) vectors commonly used to deliver gene therapies into cells. This packaging limitation has forced researchers to explore more complex and less-proven strategies.

Ascidian's ACDN-01 is designed to sidestep this fundamental challenge. Instead of attempting to replace the entire faulty gene, it targets the gene's messenger RNA (mRNA) transcript—the temporary instruction manual the cell uses to build a protein. The therapy uses a specially designed RNA editor molecule to find the mutated section, or exon, within the ABCA4 pre-mRNA and seamlessly replace it with a correct, healthy version. This allows the cell's own machinery to produce a full-length, functional ABCA4 protein, all without altering the patient's underlying DNA.

The upcoming oral presentation at ASGCT will detail the non-clinical development and, most importantly, the first-in-human clinical safety of ACDN-01. This initial data is a major de-risking event, as a favorable safety profile would bolster confidence in the RNA exon editing approach and pave the way for further clinical investigation into the therapy's effectiveness.

Beyond CRISPR: The Promise of Rewriting RNA

The technology underpinning Ascidian's pipeline represents a distinct and potentially safer alternative to DNA-based gene editing tools like CRISPR. While CRISPR-based systems make permanent changes to the genome, carrying the risk of unintended, off-target DNA mutations, RNA editing is transient. Because RNA molecules have a limited lifespan within the cell, the edits are not permanent, and the therapy does not involve introducing foreign enzymes that could trigger an immune response.

This approach allows for the correction of genetic errors with the durability of a one-time gene therapy but without the risks associated with irreversible genomic modification. It also enables the correction of very large genetic errors, a key advantage for diseases caused by mutations spanning large sections of a gene.

"The data we are presenting at ASGCT reflect both meaningful clinical progress and the growing versatility of our platform," said Michael Ehlers, M.D., Ph.D., Founder, President and Chief Executive Officer of Ascidian Therapeutics, in a company statement. "From our first clinical insights in Stargardt disease to emerging approaches targeting repeat expansion biology, we are reaching beyond conventional genetic medicines to provide new therapeutic possibilities."

The Engine of Innovation: AI-Powered Discovery

Beyond its lead program in Stargardt disease, Ascidian will also showcase the engine driving its innovation: an RNA discovery platform powered by artificial intelligence and machine learning. In a separate oral presentation, the company will demonstrate how it leverages high-throughput screening and computational biology to efficiently identify and optimize RNA exon editors for a wide array of genetic targets.

This AI/ML-enabled platform is crucial for accelerating the design and testing of new therapeutic candidates. By analyzing vast datasets, the system can predict which RNA editor designs will be most effective and specific, significantly reducing the time and resources required for early-stage drug development. This capability is key to the company's strategy of building a broad pipeline of therapies across multiple disease areas, including retinal, neurological, and neuromuscular disorders.

The presentation will highlight how this integration of AI and biology enables the rapid expansion of Ascidian's therapeutic toolkit, positioning the company to tackle a diverse range of genetic conditions that have remained beyond the reach of other therapeutic modalities.

Expanding the Pipeline to Neurological Disorders

Proof of the platform's expanding reach will be presented in a poster session detailing a preclinical program for repeat expansion disorders. These conditions, which include devastating neurodegenerative diseases like Huntington's disease, spinocerebellar ataxia, and myotonic dystrophy, are caused by the abnormal expansion of repetitive DNA sequences.

Ascidian's novel strategy involves modulating the splicing of a gene called MSH3. This gene is involved in DNA repair and has been shown to contribute to the progressive, age-related expansion of the toxic DNA repeats that drive disease pathology. By using a targeted RNA approach to reduce functional MSH3 protein, Ascidian aims to slow or halt this somatic expansion, thereby modifying the course of the disease at its source. This preclinical data represents a significant step toward applying the company's RNA-targeting expertise to the complex challenges of neurodegeneration.

Finally, underscoring its readiness for advanced clinical development, Ascidian's SVP of Operations, John Kerwin, Ph.D., will participate in a manufacturing symposium to discuss the process innovations behind ACDN-01. The company will highlight significant productivity gains in its manufacturing process, demonstrating the establishment of a robust and scalable system essential for supporting late-phase clinical trials and, ultimately, delivering these next-generation therapies to patients in need.